BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...MPS II, Hunter syndrome). The biotech has that drug’s local rights under a deal with GC Pharma...
BioCentury | Oct 21, 2020
Product Development

CEPI contracts for 1B COVID-19 vaccine doses

...Wednesday that is has contracted with Biofabri, a Spanish vaccine developer and manufacturer, and with GC Pharma...
...has reserved capacity to produce 500 million doses of vaccines by May 2022. Biofabri and GC Pharma...
...was created to provide equitable global access to COVID-19 vaccines. Steve Usdin Coalition for Epidemic Preparedness Innovations (CEPI) GC Pharma Biofabri COVID-19 cov19pol cov19counter COVAX chs2020 cov19pol...
BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos, Associate Editor Green Cross LabCell Corp. GC Pharma Artiva...
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...co-leading the alliance, which welcomed four new members Thursday: ADMA Biologics Inc. (NASDAQ:ADMA), BioPharma Plasma, GC Pharma...
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

...Hong Kong. In the same four territories, it has exclusive rights to market Hunterase from Green Cross Corp....
BioCentury | Jan 11, 2019
Company News

Canbridge, Green Cross in China deal for MPS II therapy

...Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp....
...Green Cross Corp., Yongin-si, South Korea Canbridge Pharmaceuticals Inc., Beijing, China Business: Endocrine/Metabolic Sandi Wong Hunterase (GC1111) Canbridge Pharmaceuticals Inc. GC Pharma Iduronate...
BioCentury | Jan 8, 2019
Company News

Canbridge, Green Cross in China deal for MPS II therapy

...Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp....
...see "Regulatory Reforms in China Spark Samsung Bioepis' Deal with 3SBio" ). Sandi Wong Hunterase (GC1111) Canbridge Pharmaceuticals Inc. GC Pharma Iduronate...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Pulmonary arterial hypertension Interim Phase III data; submit NDA 1H19; YE19 MacroGenics Inc. (NASDAQ:MGNX) / Green Cross Corp....
BioCentury | Nov 30, 2018
Financial News

Feldan brings series A total to $13.8M

...cells. In September, Felden raised $12.5 million in the A round led by new investor Green Cross Corp....
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

...BioCentury Online Intelligence; company websites and interviews Company First-generation product Description Status Indication Next-generation technology Green Cross Corp....
Items per page:
1 - 10 of 108
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...MPS II, Hunter syndrome). The biotech has that drug’s local rights under a deal with GC Pharma...
BioCentury | Oct 21, 2020
Product Development

CEPI contracts for 1B COVID-19 vaccine doses

...Wednesday that is has contracted with Biofabri, a Spanish vaccine developer and manufacturer, and with GC Pharma...
...has reserved capacity to produce 500 million doses of vaccines by May 2022. Biofabri and GC Pharma...
...was created to provide equitable global access to COVID-19 vaccines. Steve Usdin Coalition for Epidemic Preparedness Innovations (CEPI) GC Pharma Biofabri COVID-19 cov19pol cov19counter COVAX chs2020 cov19pol...
BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos, Associate Editor Green Cross LabCell Corp. GC Pharma Artiva...
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...co-leading the alliance, which welcomed four new members Thursday: ADMA Biologics Inc. (NASDAQ:ADMA), BioPharma Plasma, GC Pharma...
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

...Hong Kong. In the same four territories, it has exclusive rights to market Hunterase from Green Cross Corp....
BioCentury | Jan 11, 2019
Company News

Canbridge, Green Cross in China deal for MPS II therapy

...Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp....
...Green Cross Corp., Yongin-si, South Korea Canbridge Pharmaceuticals Inc., Beijing, China Business: Endocrine/Metabolic Sandi Wong Hunterase (GC1111) Canbridge Pharmaceuticals Inc. GC Pharma Iduronate...
BioCentury | Jan 8, 2019
Company News

Canbridge, Green Cross in China deal for MPS II therapy

...Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp....
...see "Regulatory Reforms in China Spark Samsung Bioepis' Deal with 3SBio" ). Sandi Wong Hunterase (GC1111) Canbridge Pharmaceuticals Inc. GC Pharma Iduronate...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Pulmonary arterial hypertension Interim Phase III data; submit NDA 1H19; YE19 MacroGenics Inc. (NASDAQ:MGNX) / Green Cross Corp....
BioCentury | Nov 30, 2018
Financial News

Feldan brings series A total to $13.8M

...cells. In September, Felden raised $12.5 million in the A round led by new investor Green Cross Corp....
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

...BioCentury Online Intelligence; company websites and interviews Company First-generation product Description Status Indication Next-generation technology Green Cross Corp....
Items per page:
1 - 10 of 108